|Description||Bicalutamide is a non-steroidal androgen receptor (AR) antagonist with IC50 of 0.16 μM.|
ODM-201 is a new-generation, potent and selective androgen receptor (AR) inhibitor which is potential useful for treatment of castration-resistant prostate canc...
GLPG0492 R enantiomer
The R-enantiomer of GLPG0492 which is a selective androgen receptor modulator, could be effective in decreasing muscle loss.
N-desmethyl Enzalutamide is a major metabolite of Enzalutamide. Enzalutamide is an androgen-receptor (AR) antagonist (IC50 = 36 nM) in LNCaP cells that inhibits...
Pyrvinium pamoate, a nonabsorbed anthelmintic drug, is a potent androgen receptor inhibitor and a selective WNT pathway inhibitor. Pyrvinium pamoate is a potent...
ASC-J9 is an AR degradation enhancer, suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen rece...
CH5137291 is a potent androgen receptor (AR) pure antagonist which did not produce the agonist metabolite with AR nuclear translocation-inhibiting activity. It ...
Enzalutamide is an androgen-receptor (AR) antagonist with IC50 of 36 nM. It inhibits the activity of prostate cancer cell Ars, which over expressed in prostate ...
GLPG0492, a selective androgen receptor modulator, could be effective in decreasing muscle loss. The treatment study against Duchenne muscular dystrophy of it h...
AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. AZD3514 is being evaluated in a Phase I clinical trial in patie...
GSK-2881078, an indole derivative, has been found to be an androgen receptor modulator that could probably be effective against Cachexia. It is still under Phas...
ORM-15341, an androgen receptor antagonist, could have potential effect against prostate cancer and commonly found as an active main metabolite of ODM-201. IC50...
BMS-564929 is a novel androgen receptor (AR) modulator (Ki= 2.11 nM) which has been advanced to clinical trials for the treatment of age-related functional decl...
ARN-509, also known as JNJ-56021927, is an androgen receptor antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby p...
MI-136, with the potential to treat refractory prostate cancer, inhibits DHT-induced expression of androgen receptor (AR) target genes. In vitro: Treatment with...
Cortexolone 17 alpha-propionate
Cortexolone 17 alpha-propionate, also called as CB-03-01, belonging to the family of ester derivatives of cortexolone, is a potent and topical and peripherally ...
BX341, also known as bifluranol, is a new fluorinated bibenzyl anti-androgen and one of a series of bibenzyls designed to present some of the hormonal propertie...
Andarine is a selective non-steroidal androgen receptor (AR) agonist with Ki of 4 nM, tissue-selective for anabolic organs.
Bicalutamide is a non-steroidal androgen receptor (AR) antagonist with IC50 of 0.16 μM.
Cyproterone acetate is a synthetic derivative of 17-hydroxyprogesterone, and acts as an androgen receptor antagonist as well as a weak progesterone receptor ago...
LGD-2226 is a selective androgen receptor modulator used in the treatment of muscle wasting and osteoporosis, shows to have an anabolic effect on muscle and bon...